Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07043803 · ClinicalTrials.gov registry record · NA
Reduction of Anticholinergic Medications Among Persons With Schizophrenia or Other Psychiatric Disorders
A NA study of Bipolar Disorder and Schizoaffective Disorder, sponsored by University of Pittsburgh.
- Recruiting
- Registry status
- NA
- Development phase
- 111
- Enrollment target
- 4
- Study locations
NCT07043803: Recruiting NA study of Bipolar Disorder and Schizoaffective Disorder, sponsored by University of Pittsburgh.
NCT07043803 is a NA study of Bipolar Disorder and Schizoaffective Disorder that is actively recruiting participants, run by University of Pittsburgh. The registered enrollment target is 111 participants, below the 332-participant average among 162 other Bipolar Disorder trials with a reported enrollment target (67% lower). The trial reports 4 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07043803, a NA study of Bipolar Disorder and Schizoaffective Disorder, is actively recruiting participants, sponsored by University of Pittsburgh.
- RECRUITING
- Registry status
- NA
- Development phase
- 111 participants
- Enrollment target
- 4
- Study locations
Study Summary
The goal of this study is to reduce Anticholinergic Medication (ACM) in persons with psychoses or serious mental illness, when these medications are no longer needed.
Primary Outcome
For the primary outcome, reduction of anticholinergic medications (benztropine and/or trihexyphenidyl) will be computed as a percentage reduction from baseline. Those participants who discontinued fully will be considered as having a 100% reduction, and those who tapered but did not discontinue will be computed as a percentage reduction from baseline, and those participants who did not discontinue at all will be considered to have a zero-percentage reduction. This anticholinergic medication redu
Conditions Studied
Interventions
- OTHER Reduction of anticholinergic medication
Study Locations (4)
Pennsylvania
- Western Behavioral Health of the Alleghenies - Altoona
- UPMC Western Behavioral Health at Safe Harbor - Erie
- Western Behavioral Health Mon Yough - McKeesport
- Comprehensive Recovery Services (Pittsburgh) of Western Psychiatric Hospital, Ambulatory Clinics and Residential Programs - UPMC, Pittsburgh, PA - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2025-07-16 |
| Est. Completion | 2026-05 |
| Phase | NA |
What NCT07043803 shows while recruiting
NCT07043803 is an interventional study that assigns participants to a tested intervention. The registered 111 participants enrollment target is mid-sized for trials with a published cap, below the 332-participant average among 162 other Bipolar Disorder trials with a reported enrollment target (67% lower).
The record links to 4 conditions, with Bipolar Disorder appearing as the primary indexed condition, and to 1 intervention - of which Reduction of anticholinergic medication is the first listed.
NCT07043803 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07043803 about?
NCT07043803 is a clinical study titled "Reduction of Anticholinergic Medications Among Persons With Schizophrenia or Other Psychiatric Disorders". The goal of this study is to reduce Anticholinergic Medication (ACM) in persons with psychoses or serious mental illness, when these medications are no longer needed.
What is the current status of trial NCT07043803?
This trial is currently recruiting. It is a NA study. The enrollment target is 111 participants. The study started on 2025-07-16. Estimated completion is 2026-05.
What conditions does trial NCT07043803 study?
This clinical trial studies the following conditions: Bipolar Disorder, Schizoaffective Disorder, Psychiatric Disorders, Schizophenia Disorder.
What interventions are being tested in trial NCT07043803?
The interventions under investigation include: Reduction of anticholinergic medication (OTHER).
Who is sponsoring clinical trial NCT07043803?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07043803 being conducted?
This trial has 4 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bipolar Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07043803's enrollment target sits among peer trials
111 61st of 162 higher than 102 of 162 other Bipolar Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bipolar Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Taking Action for College Students
RECRUITING · NA
-
Getting Out of the House: Using Behavioral Activation to Increase Community Participation
RECRUITING · NA
-
Intermittent Theta Burst Stimulation (iTBS) for Emotion Regulation in Bipolar Disorder
RECRUITING · NA
-
Healthy Lifestyles in Bipolar Disorder: Bay Area Study
RECRUITING · NA
-
A Future Thinking Intervention for Comorbid Tobacco Use Disorder and Bipolar Disorder
RECRUITING · NA
-
Use of Ketosis in Modulating Metabolic Pathways in Bipolar Disorder
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03875716 · 111 participants · NA
Study of De_Intensified Postoperative Radiation Therapy for HPV Associated Oropharyngeal Squamous Cell Carcinoma
- NCT04693468 · 111 participants · Phase 1
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial
- NCT05263050 · 111 participants · Phase 2
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
- NCT05600842 · 111 participants
De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI